Recent Headlines
Within Biotechnology
National Brain Tumor Society Opens New Funding Call for Its Oligodendroglioma Research Fund
Request for Applications seeks proposals for research on clinically relevant biomarkers for oligodendroglioma tumors, closes January 15, 2016. - December 18, 2015 - National Brain Tumor Society
MiTeGen Announces Diode Beam Stop License Agreement with Lawrence Berkeley Laboratory
MiTeGen LLC, a provider of innovative consumables for X-ray diffraction, crystallography and protein crystallization to academic, pharmaceutical, industrial and government researchers around the world, announced that it has signed an exclusive licensing agreement with Lawrence Berkeley National... - December 17, 2015 - MiTeGen, LLC
VIRUN NutraBIOsciences Collaborates with Otwo Biotech Shenzhen; 6 New Patent Applications in 2015; Virun’s New Facility is High-Tech; New Webinar Takes a Look Inside
VIRUN continues its’ interstellar growth by working with Chinese company Otwo Biotech of Shenzhen to bring new highly concentrated EPA DHA Omega products to market. Six new patent applications added to an already robust holdings. Virun’s new facility in Pomona, CA. nears completion and boasts State of the Art, eco-friendly functionalism, that includes heightened spray drying capabilities. A Live, upcoming Webinar, Feb. 2016, showcasing an "Inside Look" into VIRUN manufacturing and R&D. - December 16, 2015 - VIRUN
Recursion Pharmaceuticals Receives $2.6 Million in Follow-on Seed Funding
Funding will be used to accelerate and scale the company’s proprietary drug discovery platform. - December 08, 2015 - Recursion Pharmaceuticals
NuvOx Pharma Receives FDA Orphan Drug Designation for Radiosensitizer for Glioblastoma
Tucson based pharmaceutical company NuvOx Pharma announced today that it has secured orphan drug designation from the FDA for its investigational drug NVX-108 for treatment of Glioblastoma. Orphan status provides NuvOx with development and commercial incentives such as tax credits for qualified clinical testing and market exclusivity for 7 years after the marketing approval is granted. - December 07, 2015 - NuvOx Therapeutics
ImaBiotech’s Multimaging™ Technology Chosen by Dermira for Its Skin Disposition Study
ImaBiotech today announced that Dermira, Inc., a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, chose ImaBiotech’s Multimaging technology for a skin disposition study in Yorkshire pigs. Dermira presented the... - December 07, 2015 - Imabiotech
F2G Ltd Announces the Acceptance of F901318 to Participate in the EMA’s Adaptive Pathways Pilot Programme
F2G Ltd, a UK based antifungal drug discovery and development company, today announced that its novel systemic antifungal product F901318 has been accepted to participate in the European Medicines Agency’s (EMA) Adaptive Pathways pilot programme. Initiated in March 2014, the Adaptive... - December 03, 2015 - F2G Ltd
Bioo Scientific Launches Completely Gel-Free or Low Input Small RNA Library Prep Kit
Bioo Scientific recently launched the NEXTflex™ Small RNA-Seq Kit v3, which improves small RNA analysis by making the library prep protocol completely gel-free or allowing for low-input small RNA library preparation. This kit also reduces the biases associated with small RNA sequencing by... - November 25, 2015 - Bioo Scientific
The MaxSignal Colistin ELISA Test Kit Can Help Prevent the Antibiotic Apocalypse by Keeping Last Resort Drugs Out of the Food Supply
Colistin resistance likely emerged after the drug was overused in farm animals. Colistin is intended to be used by physicians as a drug of last resort to treat Gram-negative superbug infections, but has been overused in agriculture. Bioo Scientific’s MaxSignal® Colistin ELISA Test Kit is the only commercially available ELISA optimized for the screening of colistin in poultry and other meat samples and eggs, to prevent the spread of colistin resistance by keeping colistin out of the food supply. - November 25, 2015 - Bioo Scientific
Aurora Scientific Inc. Unveils New Brand and Celebrates the Official Opening of a New Manufacturing Facility
On October 8, 2015, Aurora Scientific, a science and technology firm in Aurora, ON welcomed guests to celebrate the official launch of their new brand and grand opening of their new manufacturing facility. The event brought together local suppliers and dignitaries, valued clients, families and friends, marking a milestone for the growing company. - November 21, 2015 - Aurora Scientific Inc.
Altogen Biosystems In Vivo Pancreas Kit Has Applications for Diabetes Mellitus and Pancreatic Cancer
As featured by Science magazine, Altogen Biosystems offers a popular line of in vivo transfection reagent kits that include polymer, liposome, nanoparticle and PEG-liposome-based in vivo transfection kits as well as in vivo kits dedicated to targeting tissues, one of which is highlighted here: the... - November 21, 2015 - Altogen Biosystems
Two Research Reports Cite HemogloBind™ for Highly Efficient Sample Preparation
Biotech Support Group reports on two recent research reports which describe the simplicity and efficiency of their proteomic sample preparation technology for hemoglobin depletion. - November 20, 2015 - Biotech Support Group
Update on Glycomics - Achieve Safe, Easy, and Accurate O-Glycan Analysis with BlotGlyco® O-Glycan Sample Preparation Kit
MoBiTec to launch Sumitomo's BlotGlyco® O-Glycan Sample Preparation Kit, a streamlined process for releasing and purifying O-glycans for detection by HPLC, LC-MS, and MALDI-TOF MS. - November 19, 2015 - MoBiTec GmbH
Prosidyan Announces FDA 510(k) Clearance of FIBERGRAFT BG Morsels for Postero-Lateral Spinal Fusion
NJ-based Prosidyan (www.prosidyan.com), developer of proprietary fiber-based bioactive glass products, announced today that it has received FDA 510(k) clearance of FIBERGRAFT BG Morsels for Postero-lateral Spinal Fusion. FIBERGRAFT BG Morsels is an ultra-porous Bone Graft Substitute, made entirely... - November 16, 2015 - Prosidyan, Inc.
Rite Aid First U.S. Drugstore Chain to Offer Harmonyx Genetic Testing to Customers
Tests help determine most effective medication therapy based on an individual’s genetic makeup - November 12, 2015 - Harmonyx Diagnostics
Successful Atlanta 8.5K Closes Event Season
Walkers and runners at the Nov. 7 Starry Night Atlanta 8.5K raised more than $120,000 to benefit the Pediatric Brain Tumor Foundation. More than 600 supporters gathered for the evening 8.5K at Centennial Olympic Park to honor local children with brain tumors, our Stars: Andrea, Anna, Ascher,... - November 12, 2015 - Pediatric Brain Tumor Foundation
Bioo Scientific Showcases Amplicon Panels and Solutions for Liquid Biopsy Analysis at AMP 2015
At the upcoming Association of Molecular Pathologists (AMP) 2015 Annual Meeting in Austin, TX, Bioo Scientific is launching library preparation solutions ideal for the reduced bias and increased sensitivity, flexibility and speed needed by molecular pathologists for next-generation sequencing applications. These include the NEXTflex Amplicon Panels, the NEXTflex Amplicon Studio service, and the new NEXTflex BRCA1 and BRCA2 Panels. - November 07, 2015 - Bioo Scientific
Fannin Innovation Studio Forms Molecular Therapeutics Company Exotect, LLC.
Researchers behind Exotect LLC have honed in on a novel molecular pathway that controls the overproduction of mucus during asthma attacks. More than 25 million people suffer with asthma, a chronic disease in which airways become inflamed, swell and produce excess mucus making it difficult to breathe. - November 07, 2015 - Fannin Partners, LLC
Zenalux Announces Grants from the National Institute of Health for Cancer Screening
Zenalux Biomedical, Inc., a leader in biophotonic diagnostics, has been awarded a grant from the National Institute of Health (NIH) to further develop the Zenascope® to screen for cancer by employing imaging and reducing operator error. Zenalux is also participating in an Academic Industry... - November 06, 2015 - Zenalux Biomedical, Inc.
FastQS Announces Launch of Complaint Management Solution for Medical Device Companies
FastQS, today, announced the launch of its modern cloud-based Complaint Management Solution designed specifically for the medical device industry. With FastQS, medical device companies can easily process complaints paperlessly and compliantly. Robust complaint management is a requirement under the... - November 05, 2015 - FastQS
PBTF, ABC2 Cofund Pediatric Brain Cancer Screening Research
The Pediatric Brain Tumor Foundation and ABC2 (Accelerate Brain Cancer Cure) are working together to fund the development of immunosignature-based blood tests for detecting, classifying and monitoring pediatric medulloblastoma over time. - November 04, 2015 - Pediatric Brain Tumor Foundation
DNAe Secures £25 Million ($38 Million) Bank Facility to Fund Development of Pioneering Point-of-Need IVD for Serious Blood Infections
DNAe, the inventors of semiconductor DNA sequencing technology, have secured a bank facility of £25 million ($38 million) to fund the final development stages of DNAe Diagnostics’ revolutionary point-of-need test for serious blood infections. This will include clinical trials targeted for 2016 and product launch in 2017. - November 04, 2015 - DNA Electronics
RxGenesys, LLC. Validates Claims via Double Blind Independent Study by Princeton Consumer Research
RxGenesys Complete Skin Care System(R) Reduces Fine Lines and wrinkles by 56% and Improves Radiance, Elasticity and Moisture Levels After Eight Weeks. Watch the interview at: http://youtu.be/9RySXfUbm3s RxGenesys, a developer, manufacturer and marketer of state-of-the-art skin care, based on a... - October 30, 2015 - RxGenesys
New Sealed Tubing Ends from AdvantaPure(R) Reduce Operational Costs and Improve Efficiencies; Help to Maintain a Sterile and Closed Fluid Transfer System
Now available from AdvantaPure is its AdvantaFlex(R) biopharmaceutical grade tubing with pre-sealed ends. The ends maintain a closed, sterile fluid path system for sampling and storage uses in biopharma and pharmaceutical applications. Sealed Tubing Ends save time compared to sealing on site and reduce the need for expensive aseptic connectors. The Single-Use product is supplied gamma sterilized and ready for immediate use in both upstream and downstream applications. - October 29, 2015 - AdvantaPure
Clinical Trials in Russia. The Third Quarter 2015.
The Ministry of Health of the Russian Federation approved 203 new clinical trials of all types, including local and bioequivalence studies, during the 3rd Quarter of 2015. This represents a 13% increase over the same period of last year. - October 25, 2015 - Synergy Research Group
Fannin Innovation Studio’s Atul Varadhachary Appointed to Jones Health Care Advisory Board
Diverse group of industry leaders to enhance Rice University’s Health Care Initiative. - October 24, 2015 - Fannin Partners, LLC
Procyrion Expands Team in Preparation for First Human Trials
Houston medical device startup names Joseph Choi clinical development engineer. - October 24, 2015 - Procyrion Inc
Pregmama Announces First Pregnancy in Its Pilot Clinical Trial to Treat Infertility in Women Over 35
Rolling back the clock on infertility - October 22, 2015 - Pregmama LLC
Bioo Scientific Releases Low-Input, High Multiplexing Library Prep Solution for SeqCap Target Capture
Bioo Scientific is releasing the new NEXTflex™ Rapid Pre-Capture Combo Kit, a complete low-input library prep solution with the ability to multiplex up to 96 samples, containing the library prep reagents, barcodes, blockers and post-capture amplification reagents required for SeqCap target capture with Roche NimbleGen’s SeqCap EZ solution-based capture system. With this kit, libraries can be constructed from 10 ng of input DNA in only 2 hours. - October 21, 2015 - Bioo Scientific
VMRD's Anaplasma cELISA Antibody Test Kit v2 Now Available
VMRD is excited to announce release of version 2 (V2) of its bovine Anaplasma cELISA antibody test kit. This new version includes several long-requested customer improvements such as: * Shorter run time: 30 minutes faster / 100 minutes total * Easier to use: requires fewer steps and eliminates... - October 15, 2015 - VMRD, Inc.
Altogen Biosystems Develops Powerful In Vivo RNAi Research Tool for Oncology
Lipid-based liposomes of nanometer size are one of the most powerful molecules for delivery of novel therapeutics into target tissues enabling targeted cancer therapeutics. Pharma companies actively investigating new RNAi-based therapeutics where cargo molecules such as a small proteins, DNA,... - October 13, 2015 - Altogen Biosystems
T-Cell Immunotherapy Market to be Worth USD 30 Billion by 2030, Predicts Roots Analysis
The “T-Cell Immunotherapy Market, 2015-2030” report provides an extensive study of the field of T-cell immunotherapy. With no marketed products, this emerging field is still in its infancy; the report provides a comprehensive view of the market segmented into the following three sub-groups: CAR-T therapies, TCR therapies and TIL therapies. - October 13, 2015 - Roots Analysis
CHI to Host Roundtable Discussions at Optimizing Bioassays for Biologics Conference
Moderated by Drs. Han Li, Bristol-Myers Squibb; Maura C. Kibbey, United States Pharmacopeia (USP); and Max L. Tejada, Gilead Sciences - October 10, 2015 - Cambridge Healthtech Institute
Bioo Scientific Showcases Solutions Designed to Improve Exome Capture at ASHG 2015
At ASHG 2015, Bioo Scientific is launching a number of new kits for the improvement of in-solution exome and custom target capture. These kits offer optimized library prep, blocking and barcoding, interfacing with Agilent SureSelect XT and XT2 systems and Roche’s Nimblegen SeqCap systems. ASHG is the largest human genetics meeting and expo worldwide, providing a forum for the presentation and discussion of cutting-edge science in all areas of human genetics. - October 09, 2015 - Bioo Scientific
Public Health of Castilla La Mancha Opts for the Legipid Rapid Test for Detecting Legionella in Water
The Public Health Laboratories of Castilla La Mancha (Spain) have introduced the Legipid® Legionella Fast Detection kit to determine Legionella in water. This kit was developed by the company Biotica Bioquimica Analitica (www.biotica.es), which belongs to the Science, Technology and Business Park of the Universitat Jaume I (Espaitec). - October 08, 2015 - Biotica Bioquimica Analitica
Procyrion Inc. Earns €30,000 for Circulatory Support Pump in International Life Sciences Competition
Houston heart pump developer Procyrion Inc. (http://www.procyrion.com) earned the 2015 Universal Biotech Innovation Prize for Aortix™, a catheter-based circulatory support device. With the top two most innovative projects, Procyrion and Pixium Vision, will share a grant award and a year of... - October 08, 2015 - Procyrion Inc
New Research Identifies Leading Clinical CROs Best Positioned for Future Success
New Research Identifies Future Leadership and Benchmarks CRO Operational Performance with over 160 Clinical Outsourcing Decision Makers - October 07, 2015 - Life Science Strategy Group, LLC
Northern California Motorcyclists Ride for Kids with Brain Tumors
Nearly 200 motorcyclists gathered for the Northern California Ride for Kids over the weekend to support children battling brain tumors. As of ride time, the family-friendly motorcycle event in Fairfield, Calif., had raised $59,342 to support the Pediatric Brain Tumor Foundation. The event honored... - October 07, 2015 - Pediatric Brain Tumor Foundation
Recursion Pharma Receives Orphan Drug Designation for Hereditary Stroke Disorder
Recursion Pharmaceuticals, a drug discovery start-up company, announced receipt of an Orphan Drug Designation from the FDA for the use of Tempol for the treatment of Cerebral Cavernous Malformation, a hereditary stroke disease. Recursion expects this will be the first of many potential treatments identified using their proprietary drug discovery platform. - October 05, 2015 - Recursion Pharmaceuticals
ELISA Biology Contract Research Services Provided by Altogen Labs
Enzyme Linked Immunosorbent Assay (ELISA) is a widely used laboratory research assay designed for detecting and quantifying substances such as peptides, proteins, antibodies and hormones. ELISA is a very accurate, highly sensitive and specific immunoassay in comparison to other types of common... - October 03, 2015 - Altogen Labs
Regulate Gene Expression with Altogen Labs RNAi Technology
Ribonucleic Acid or RNA is a molecule critical to biology because it is behind the coding, regulation and expression of genes. With the RNA Interference or RNAi technology service offered by Altogen Labs it is possible to effectively regulate gene expression. Moreover, Altogen Labs has developed... - October 03, 2015 - Altogen Labs
Novatein Biosciences Launches Cancer Biomarker ELISA Kits
Novatein Biosciences (www.novateinbio.com) is proud to add Cancer Biomarker ELISA Kits to its expanding product line. - October 03, 2015 - Novatein Biosciences
Altogen Biosystems Releases Competitive In Vivo Polymer Kit
Altogen Biosystems has exclusively developed a highly effective In Vivo Polymer Transfection Kit that is capable of delivering siRNA, mRNA, small proteins, and DNA into various rodent tissues for pre-clinical and laboratory research. The efficacy of the Altogen Biosystems new in vivo transfection... - October 02, 2015 - Altogen Biosystems
New Generation of Tissue-Targeted Nanoparticle Based In Vivo Transfection Kit for Animal Research Developed by Altogen Biosystems
Researchers can now effectively deliver molecular targeted medicines into a myriad of tissues using nanotechnology. Altogen Biosystems has developed a new generation of highly efficient Nanoparticle-based In Vivo Transfection Kit that it exclusively manufactures. Nanoparticle technology can be... - October 02, 2015 - Altogen Biosystems
Altogen Biosystems Offers PEG-Liposome In Vivo Transfection Kit
Altogen Biosystems has developed a highly efficient in vivo transfection reagent capable of delivery cargo molecules (siRNA, miRNA, pDNA, and small proteins) into multiple tissues including spleen, kidney, pancreas, liver, and tumors. In vivo transfection is a laboratory research method utilized by... - October 02, 2015 - Altogen Biosystems
Procyrion's Circulatory Pump for Late-Stage Heart Failure Earns Spot in TCT Interventional Innovation "Shark Tank” Competition
Diagnostic and therapeutic modalities presented at Transcatheter Cardiovascular Therapeutics annual scientific symposium. - October 02, 2015 - Procyrion Inc
Houston Heart Pump Developer Procyrion Inc. Earns $20,000 Grand Prize in "Create the Future" Design Contest
Out of 1,159 forward-thinking engineering innovations from 60 countries, micro heart pump developer Procyrion Inc. of Houston, Texas earned the $20,000 grand prize in the 2015 “Create the Future” Design Contest, organized by the publishers of NASA Tech Briefs and Medical Design Briefs... - October 01, 2015 - Procyrion Inc
Bostonians Walk, Run for Kids with Brain Tumors
About 200 Bostonians gathered on Sept. 26 for the Starry Night Boston 8.5K, benefiting the Pediatric Brain Tumor Foundation. At start time, the event had raised $27,074 to help fund the foundation’s lifesaving research and life-changing family support programs. The crowd gathered for the... - September 30, 2015 - Pediatric Brain Tumor Foundation
Motorcyclists Contribute $167,000 to Aid Sick Children
From the Las Vegas Strip to the Capitol area, more than 700 motorcyclists gathered for children battling brain tumors over the weekend. As of ride time, the family-friendly Baltimore-Washington and Las Vegas Ride for Kids events had raised $167,459 to support the Pediatric Brain Tumor... - September 30, 2015 - Pediatric Brain Tumor Foundation
Ixogel® is Granted QIDP Status by the US Food and Drug Administration
Ixodes AG, a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention of Lyme Disease, today announced that the U.S. Food and Drug Administration (FDA) has designated the company's lead product candidate, Ixogel®, as a Qualified Infectious Disease Product (QIDP) for the prevention of Lyme Disease after a tick bite and is working with the company on the phase III protocol. Special Protocol Assessment (SPA) confirmation expected soon. - September 29, 2015 - Ixodes AG